IRIDEX Corporation — Form 10-Q Summary
Business context and reporting period
Unaudited results for the quarter and six months ended July 2, 2011. IRIDEX develops and sells medical laser systems, delivery devices, consumables, and related services in ophthalmology and aesthetics; it sells internationally through distributors and sells aesthetics products directly in France.
Financial performance and liquidity
| Metric | Three months ended July 2, 2011 | Prior-year quarter | Six months ended July 2, 2011 | Prior-year six months |
|---|---|---|---|---|
| Revenue | $10.798m | $9.890m | $22.010m | $20.648m |
| Gross profit / margin | $4.877m / 45.2% | $4.536m / 45.9% | $10.115m / 46.0% | $9.761m / 47.3% |
| Operating income | $0.435m | $0.135m | $1.047m | $0.738m |
| Net income | $0.909m | $0.814m | $1.475m | $1.299m |
| Diluted EPS | $0.09 | $0.08 | $0.14 | $0.13 |
- Quarterly product revenue was $8.884m, up from $7.805m; service revenue was $1.914m, down from $2.085m. Six-month product and service revenue were $17.955m and $4.055m, respectively.
- For the six months, ophthalmology revenue was $16.281m and aesthetics revenue was $5.729m. International sales were $10.054m, or about 45.7% of total revenue.
- Gross margin declined year over year in both periods. Management attributed the six-month decline chiefly to less favorable manufacturing variances and product mix.
- Cash and cash equivalents were $8.875m at July 2, versus $9.014m at January 1. Working capital was $19.1m, compared with $17.2m. The company reported no borrowings and had a $5.0m revolving facility available; it was compliant with its covenants.
- The cash flow statement reports $0.058m net cash provided by operations for the six months, versus $1.374m in the prior-year period; cash decreased by $0.139m. Inventory growth of $1.017m and a $0.798m decline in accrued compensation were significant uses of operating cash.
- Total liabilities were $8.704m and stockholders’ equity was $21.172m at July 2. No debt was outstanding.
Material changes versus prior period
- Quarterly revenue rose about 9% and six-month revenue about 7%. Ophthalmology growth reflected stronger domestic system sales and recurring consumables; the OEM product line was being phased out. Aesthetics revenue increased, though management described that market as challenging and sales as lumpy.
- Operating income improved, while net income also included an $0.8m legal-settlement installment in each reported period. The settlement stemmed from a 2007 patent-infringement matter; management expected the final $0.8m annual payment in the second quarter of fiscal 2012.
- IRIDEX recognized a $0.170m accumulated foreign-currency translation loss associated with closing its UK subsidiary. The balance-sheet inventory rose to $10.169m from $9.212m.
- The company repurchased 101,098 shares for approximately $0.401m during the six months, including purchases from a former transaction counterparty and under a newly authorized $2.0m repurchase program. Approximately $1.9m remained authorized at quarter-end.
Outlook, commentary, and risks
- Management said current cash, expected operating cash generation, and the credit facility should provide sufficient liquidity for the next 12 months. It anticipated higher R&D spending to replace headcount and support more product introductions, as well as higher sales and marketing spending intended to drive sales. No quantified revenue or earnings guidance was provided.
- Management warned that results and margins may fluctuate with product and geographic mix, manufacturing variances, seasonality, economic conditions, and timing of large system orders. European ophthalmology demand faced economic and competitive pressure; aesthetics demand remained sensitive to discretionary spending.
- Key risks include competition and reimbursement changes; reliance on international distributors and limited-source suppliers; regulatory approvals and ongoing FDA quality-system compliance; product defects and liability claims; and the ability to develop and commercialize new products. The company also cited the 2010 expiration of its connector patent as a potential threat to consumable probe competition.
- The filing reported no legal proceedings and stated that disclosure controls were effective as of July 2, 2011. The six-month results are not necessarily indicative of full-year performance.
Important facts for investors to verify
- Whether operating cash flow recovers from the reported $0.058m as inventory and accrued compensation movements normalize; MD&A also discusses approximately $2.1m of cash generation before working-capital changes.
- How much of reported earnings depends on the remaining legal-settlement installment and whether operating profitability is sustainable without it.
- Whether lower gross margins, inventory growth, and planned increases in R&D and selling costs affect future cash needs and profitability.
- Progress in replacing declining OEM revenue, sustaining recurring consumables sales, and expanding ophthalmology and aesthetics demand amid competition and economic uncertainty.